Skip to main content

Primary Aldosteronism: Screening and Confirmatory Testing of a Highly Underdiagnosed Disease

From the 2022 Joint Annual Meeting (recorded 6/27/2022)
Presented by Brandy Gunsolus, DCLS, MLS(ASCP)CM

Primary Aldosteronism (PA) accounts for nearly 10 percent of all hypertensive patients, but only 3 percent of hypertensive patients are tested for it. This session will discuss the renin–angiotensin–aldosterone system (RAAS), testing for PA, and direct renin concentration vs plasma renin activity. AVS testing performed during confirmatory and treatment procedures will also be discussed.

At the conclusion of this presentation, participants will be able to:

  • Identify components of the renin-angiotensin-aldosterone system (RAAS) and its implication on hypertension.
  • Describe and understand key difference between plasma renin activity (PRA) and direct renin concentration (DRC) assays.
  • Discuss proposed age-specific plasma aldosterone/plasma renin ratio (ARR) cutoffs for primary aldosteronism screening.

ASCLS is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of Chemistry (Chemistry) will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.

This Intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.